Leveraging Genomic Factors to Improve Benefit-Risk.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.
R N
RN
Schuck
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.
R
R
Charlab
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.
G M
GM
Blumenthal
D000066491:Clinical Decision-Making; D004059:Diffusion of Innovation; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D054796:Drug Dosage Calculations; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control; D005544:Forecasting; D020022:Genetic Predisposition to Disease; D023281:Genomics / Q000379:methods* / Q000639:trends; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D061214:Patient Safety; D018579:Patient Selection; D000071184:Pharmacogenomic Variants; D010641:Phenotype; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors